ClinicalTrials.gg
CompletedNCT04313244Updated Feb 7, 2024Results posted

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

A Phase 3 interventional study of 9vHPV Vaccine and Dengue Tetravalent Vaccine (TDV) in Dengue Fever, sponsored by Takeda. Completed at 4 sites in Thailand. Open to participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
9 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.

Enrollment
6th of 15
614 · median 400
Started
2021
the only one that year
Phase 3
9 of 17
1 open now
Registered
11th of 17
by date

Among the 17 studies in Dengue by Takeda, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 9 in phase 3, and was the 11th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 9 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dengue by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.

Read the detailed description

The vaccine being tested in this study is called Tetravalent Dengue Vaccine (TDV). The study will assess the immunogenicity and safety on the co-administration of 9vHPV vaccine with TDV in healthy participants aged ≥9 to \<15 years.

The study will enroll approximately 614 healthy volunteers. Participants will be randomly assigned to one of the two treatment groups-

  • Group 1
  • Group 2

All participants will receive recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) in combination with Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) injection on Day 1 (Month 0 ) followed by 9vHPV on Day 90 (Month 3) and TDV on Day 180 (Month 6) in Group 1. Participants will receive 9vHPV on Day 1 (Month 0) and Day 180 (Month 6) IM in Group 2.

This multi-center trial will be conducted in Thailand. The overall time to participate in this study is 12 months. Participants will make multiple visits to the clinic, after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Dengue Fever

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
9 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator.
  2. Participants who can comply with trial procedures and are available for the duration of follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Has an elevated oral temperature ≥38°C (≥100.4°F) within 3 days of the intended date of vaccination.
  2. Participants with , warnings and/or precautions to vaccination with Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) vaccine as specified within the prescribing information.
  3. Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease.
  4. Known or suspected impairment/alteration of immune function, including:

    1. Chronic use of oral (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed).
    2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0).
    3. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial.
    4. Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).
    5. therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0).
    6. (HIV) infection or HIV-related disease.
    7. virus infection.
    8. virus infection.
    9. Genetic immunodeficiency.
  5. Abnormalities of splenic or thymic function.
  6. Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  7. Who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to enrollment in this trial or who are planning to receive any vaccine within 28 days of trial vaccine administration.
  8. Who have used antipyretics and/or analgesic medications within 24 hours prior to vaccination. The reason for their use (prophylaxis versus treatment) must be documented. Trial entry should be delayed to allow for a full 24 hours to have passed since last use of antipyretics and/or analgesic medications.
  9. Previous and planned vaccination (during the trial conduct), against any flavivirus (except Japanese encephalitis [JE]) including dengue, yellow fever (YF) viruses or tick-borne encephalitis.
  10. Previous and planned vaccination (during the trial conduct) against HPV.
  11. Previous participation in any clinical trial of a dengue or other flavivirus (eg, West Nile [WN] virus) candidate vaccine, except for participants who received placebo in those trials.
  12. Has a current or previous infection with a flavivirus such as Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    9vHPV+TDV

    Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).

    Biological: 9vHPV Vaccine · Biological: Dengue Tetravalent Vaccine (TDV)

  • Experimental
    9vHPV

    Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).

    Biological: 9vHPV Vaccine

Interventions

  • Biological9vHPV Vaccine

    9vHPV intramuscular injection

  • BiologicalDengue Tetravalent Vaccine (TDV)

    TDV subcutaneous injection

    Also known as: TAK-003

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58

    GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.

    Time frame: Day 210 (Month 7)

Secondary outcomes

  1. Percentage of Participants With Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA)

    Seropositive for HPV is defined as anti-HPV titers greater or equal to the prespecified cutoffs for any of the 9 HPV serotypes: HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58, measured by IgGBA. The serostatus cut-off is the antibody titer level above the assay's lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of IgGBA or equivalent assay. The serostatus cut-offs for the 9 HPV serotypes: HPV-6= 9, HPV-11= 6, HPV-16= 5, HPV-18= 5, HPV-31= 3, HPV-33= 4, HPV-45= 3, HPV-52= 5 and HPV-58= 5. Percentages are rounded off to the nearest decimal point.

    Time frame: Day 210 (Month 7)

  2. GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes

    GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% (MNT50). The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only.

    Time frame: Day 120 (Month 4)

  3. Percentage of Participants With Seropositivity for Each of the 4 Dengue Serotypes

    Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.

    Time frame: Day 120 (Month 4)

  4. Percentage of Participants With Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes

    Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized for categories with at least one participant with event: trivalent (seropositive for 3 dengue serotypes), and tetravalent (seropositive for all 4 dengue serotypes). As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.

    Time frame: Day 120 (Month 4)

  5. Percentage of Participants With Solicited Local Adverse Events for 7 Days Following Vaccination by Severity

    Solicited local adverse events (AEs) (at injection site) were collected by participants using diary cards within 7 days after vaccination and included: Pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\]; erythema and swelling \[Grade 0 (\<25 millimeters \[mm\]), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. Percentages are rounded off to the nearest decimal point. The data for solicited local adverse events after any vaccination are presented. Only those categories with at least 1 participant with event are reported.

    Time frame: Up to 7 days (Day of vaccination + 6 subsequent days) after each vaccination

  6. Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 14 Days Following Vaccination by Severity

    Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and included fever, headache, asthenia, malaise, and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4 degrees Fahrenheit \[°F\]). Only categories with at least one participant with event following any vaccination are reported. Percentages are rounded off to the nearest decimal point. The data for solicited systemic adverse events after any vaccination are presented.

    Time frame: Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination

  7. Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration. Percentages are rounded off to the nearest decimal point. The data for unsolicited adverse events after any vaccination are presented.

    Time frame: Up to 28 days (Day of vaccination + 27 subsequent days) after each vaccination

  8. Percentage of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence or effect that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important which may require intervention to prevent the items listed above or may expose the participant to danger.

    Time frame: From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12])

07

Results

Posted Feb 7, 2024

Participant flow

Participants took part in the study at 4 investigative sites in Thailand from 15 May 2021 to 19 July 2022.

Participant flow — Overall Study
Milestone9vHPV+TDV9vHPV
Started307307
Completed302304
Not completed53
Withdrew: Withdrawal of consent33
Withdrew: Met exclusion criteria10
Withdrew: Invalid informed consent form (icf)10

Outcome measures

PrimaryGeometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58

GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.

Time frame:
Day 210 (Month 7)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58
titer9vHPV+TDV9vHPV
HPV-61633.693 (1465.31 to 1821.43)1790.986 (1556.08 to 2061.35)
HPV-111342.745 (1225.64 to 1471.04)1325.192 (1164.58 to 1507.95)
HPV-167777.694 (6989.76 to 8654.45)7822.564 (6701.83 to 9130.71)
HPV-182309.629 (2075.91 to 2569.66)2506.309 (2182.67 to 2877.93)
HPV-311690.941 (1529.39 to 1869.55)1736.943 (1515.05 to 1991.33)
HPV-331138.716 (1019.66 to 1271.67)1179.469 (1033.66 to 1345.84)
HPV-45504.033 (453.46 to 560.24)584.198 (509.91 to 669.31)
HPV-52585.606 (533.44 to 642.87)561.007 (492.77 to 638.69)
HPV-581163.600 (1060.23 to 1277.05)1284.504 (1130.63 to 1459.32)
SecondaryPercentage of Participants With Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA)

Seropositive for HPV is defined as anti-HPV titers greater or equal to the prespecified cutoffs for any of the 9 HPV serotypes: HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58, measured by IgGBA. The serostatus cut-off is the antibody titer level above the assay's lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of IgGBA or equivalent assay. The serostatus cut-offs for the 9 HPV serotypes: HPV-6= 9, HPV-11= 6, HPV-16= 5, HPV-18= 5, HPV-31= 3, HPV-33= 4, HPV-45= 3, HPV-52= 5 and HPV-58= 5. Percentages are rounded off to the nearest decimal point.

Time frame:
Day 210 (Month 7)
Reported as:
Number · percentage of participants
Percentage of Participants With Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA)
percentage of participants9vHPV+TDV9vHPV
HPV-6100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-11100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-16100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-18100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-31100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-33100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-45100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-52100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
HPV-58100.0 (98.5 to 100.0)99.1 (96.9 to 99.9)
SecondaryGMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes

GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% (MNT50). The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only.

Time frame:
Day 120 (Month 4)
Reported as:
Geometric mean · titer
GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes
titer9vHPV+TDV
DENV-1719.1 (577.8 to 895.0)
DENV-21691.4 (1411.0 to 2027.4)
DENV-3555.4 (462.8 to 666.6)
DENV-4494.3 (420.8 to 580.6)
SecondaryPercentage of Participants With Seropositivity for Each of the 4 Dengue Serotypes

Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.

Time frame:
Day 120 (Month 4)
Reported as:
Number · percentage of participants
Percentage of Participants With Seropositivity for Each of the 4 Dengue Serotypes
percentage of participants9vHPV+TDV
DENV-1100.0 (98.5 to 100.0)
DENV-299.6 (97.7 to 100.0)
DENV-3100.0 (98.5 to 100.0)
DENV-4100.0 (98.5 to 100.0)
SecondaryPercentage of Participants With Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes

Seropositivity is defined as a reciprocal neutralizing antibody titer ≥10 for any of the 4 dengue serotypes. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized for categories with at least one participant with event: trivalent (seropositive for 3 dengue serotypes), and tetravalent (seropositive for all 4 dengue serotypes). As prespecified in the protocol, the data for this outcome measure was collected and analyzed for participants in the 9vHPV+TDV arm group only. Percentages are rounded off to the nearest decimal point.

Time frame:
Day 120 (Month 4)
Reported as:
Number · percentage of participants
Percentage of Participants With Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes
percentage of participants9vHPV+TDV
Trivalent0.4 (0.0 to 2.3)
Tetravalent99.6 (97.7 to 100.0)
SecondaryPercentage of Participants With Solicited Local Adverse Events for 7 Days Following Vaccination by Severity

Solicited local adverse events (AEs) (at injection site) were collected by participants using diary cards within 7 days after vaccination and included: Pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\]; erythema and swelling \[Grade 0 (\<25 millimeters \[mm\]), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. Percentages are rounded off to the nearest decimal point. The data for solicited local adverse events after any vaccination are presented. Only those categories with at least 1 participant with event are reported.

Time frame:
Up to 7 days (Day of vaccination + 6 subsequent days) after each vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Adverse Events for 7 Days Following Vaccination by Severity
percentage of participants9vHPV+TDV9vHPV
Pain: Mild54.142.8
Pain: Moderate9.56.5
Pain: Severe0.70
Erythema: Mild7.50
Erythema: Moderate0.70
Swelling: Mild3.30
SecondaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) for 14 Days Following Vaccination by Severity

Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and included fever, headache, asthenia, malaise, and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4 degrees Fahrenheit \[°F\]). Only categories with at least one participant with event following any vaccination are reported. Percentages are rounded off to the nearest decimal point. The data for solicited systemic adverse events after any vaccination are presented.

Time frame:
Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 14 Days Following Vaccination by Severity
percentage of participants9vHPV+TDV9vHPV
Headache: Mild20.018.0
Headache: Moderate3.00.7
Headache: Severe0.30
Asthenia: Mild16.712.1
Asthenia: Moderate2.01.0
Asthenia: Severe0.30
Malaise: Mild17.710.5
Malaise: Moderate2.01.3
Malaise: Severe0.30
Myalgia: Mild36.127.8
Myalgia: Moderate7.92.3
Myalgia: Severe0.30.3
Fever: 38.0°C to <38.5°C2.00.3
Fever: 38.5°C to <39.0°C0.30
Fever: 39.0°C to <39.5°C0.30
SecondaryPercentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration. Percentages are rounded off to the nearest decimal point. The data for unsolicited adverse events after any vaccination are presented.

Time frame:
Up to 28 days (Day of vaccination + 27 subsequent days) after each vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination
percentage of participants9vHPV+TDV9vHPV
Percentage of Participants With Any Unsolicited AEs for 28 Days Following Vaccination8.82.6
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence or effect that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important which may require intervention to prevent the items listed above or may expose the participant to danger.

Time frame:
From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12])
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)
percentage of participants9vHPV+TDV9vHPV
Percentage of Participants With Serious Adverse Events (SAEs)10.17.2

Adverse events

Collected over All-cause mortality and serious adverse events: From first vaccination (Day 1 [Month 0]) through end of study (Day 360 [Month 12]); Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after each vaccination. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9vHPV+TDV0/307 (0%)31/307 (10.1%)253/307 (82.4%)
9vHPV0/307 (0%)22/307 (7.2%)223/307 (72.6%)
Most frequent serious events
Most frequent serious events
Event9vHPV+TDV9vHPV
COVID-19Infections and infestations26/30719/307
COVID-19 pneumoniaInfections and infestations2/3072/307
AsthmaRespiratory, thoracic and mediastinal disorders1/3070/307
BronchitisInfections and infestations1/3070/307
Foreign body in gastrointestinal tractInjury, poisoning and procedural complications1/3070/307
GastroenteritisInfections and infestations1/3070/307
Limb injuryInjury, poisoning and procedural complications0/3071/307
Road traffic accidentInjury, poisoning and procedural complications0/3071/307
Most frequent other events
Showing 10 of 26
Most frequent other events
Event9vHPV+TDV9vHPV
PainGeneral disorders225/307184/307
MyalgiaMusculoskeletal and connective tissue disorders135/30793/307
ErythemaSkin and subcutaneous tissue disorders92/30757/307
HeadacheNervous system disorders71/30759/307
SwellingGeneral disorders64/30752/307
MalaiseGeneral disorders62/30736/307
AstheniaGeneral disorders58/30740/307
FeverGeneral disorders8/3071/307
NasopharyngitisInfections and infestations3/3070/307
Dermatitis contactSkin and subcutaneous tissue disorders2/3070/307

Baseline characteristics

Randomized Set included all randomized participants, regardless of whether any dose of the investigational products (IPs) was received.

Age, Continuous
Age, Continuous(years)9vHPV+TDV9vHPVTotal
Mean11.1 ± 1.6011.3 ± 1.5911.2 ± 1.59
Sex: Female, Male
Sex: Female, Male(Participants)9vHPV+TDV9vHPVTotal
Female150156306
Male157151308
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)9vHPV+TDV9vHPVTotal
Hispanic or Latino000
Not Hispanic or Latino307307614
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)9vHPV+TDV9vHPVTotal
American Indian or Alaska Native000
Asian307307614
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)9vHPV+TDV9vHPVTotal
Thailand307307614
Height
Height(centimeters (cm))9vHPV+TDV9vHPVTotal
Mean147.68 ± 12.244148.18 ± 11.374147.93 ± 11.809
Weight
Weight(kilograms (kg))9vHPV+TDV9vHPVTotal
Mean44.21 ± 15.91344.37 ± 14.27144.29 ± 15.101
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter square (kg/m^2))9vHPV+TDV9vHPVTotal
Mean19.78 ± 4.91219.88 ± 4.76219.83 ± 4.834
08

Study locations

4 sites
  • Siriraj Hospital
    Bangkoknoi, Khet Bangkok Noi 10700, Thailand
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • The Hospital for Tropical Diseases
    Bangkok, 10400, Thailand
  • Thammasat University Hospital
    Pathum Thani, 12121, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Feb 2022, 9 months.

Results were first posted in Feb 2024, 1 year 11 months after primary completion. A results delay was requested in Jan 2023.

Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 18, 2020
StartActual
May 15, 2021
Primary completionActual
Feb 21, 2022
CompletionActual
Jul 19, 2022
Results delay requested
Jan 18, 2023
Results first posted
Feb 7, 2024
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04313244
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 18, 2020
Start date
May 15, 2021
Primary completion
Feb 21, 2022
Completion
Jul 19, 2022
Results posted
Feb 7, 2024
Last update
Feb 7, 2024

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion